We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us

Download Mobile App





Chinese Firm Sinovac Biotech Announces Positive Early Results of COVID-19 Vaccine Trials

By HospiMedica International staff writers
Posted on 16 Jun 2020
Print article
Image: CoronaVac (Photo courtesy of Sinovac Biotech Ltd.)
Image: CoronaVac (Photo courtesy of Sinovac Biotech Ltd.)
Sinovac Biotech Ltd. (Beijing, China) has announced positive preliminary results of Phase 1/2 clinical trial for the company’s COVID-19 vaccine candidate, named CoronaVac, which showed favorable immunogenicity and safety profiles.

Sinovac’s development of a vaccine against COVID-19 began in January 2020 in partnership with leading academic research institutes in China. The company received approval from China’s National Medical Products Administration (NMPA) on April 13 to conduct Phase 1/2 studies on its inactivated vaccine candidate against COVID-19 in China. The Phase 1/2 clinical trials were designed as randomized, double-blind and placebo-controlled studies. In total, 743 healthy volunteers, aged from 18 to 59 years old, enrolled in the trials. Of those, 143 volunteers are in Phase 1 and 600 volunteers are in Phase 2. There have been no severe adverse events reported in either the Phase 1 or Phase 2 trials. The Phase 2clinical trial results showed that the vaccine induces neutralizing antibodies 14 days after the vaccination with a 0,14 day schedule. The neutralizing antibody seroconversion rate is above 90%, suggesting that the vaccine candidate can induce positive immune response.

The company expects to submit a Phase 2 clinical study report and a Phase 3 clinical study protocol to NMPA in the near future and commence application of Phase 3 clinical trials outside of China. Additionally, Sinovac is collaborating with Brazil’s Instituto Butantan to prepare and conduct a Phase 3 clinical study of its inactivated vaccine candidate against COVID-19.

“Our Phase 1/2 study shows CoronaVac is safe and can induce immune response. Concluding our Phase 1/2 study clinical studies with these encouraging results is another significant milestone we have achieved in the fight against COVID-19,” said Mr. Weidong Yin, Chairman, President and CEO of Sinovac. “We have started to invest in building a manufacturing facility so that we can maximize the number of doses available to protect people from COVID-19. Like with our other vaccines, we are committed to developing CoronaVac for global use as part of our mission of supplying vaccines to eliminate human diseases.”

Related Links:
Sinovac Biotech Ltd.

Gold Member
Disposable Protective Suit For Medical Use
Disposable Protective Suit For Medical Use
Gold Member
SARS‑CoV‑2/Flu A/Flu B/RSV Sample-To-Answer Test
SARS‑CoV‑2/Flu A/Flu B/RSV Cartridge (CE-IVD)
Silver Member
Wireless Mobile ECG Recorder
NR-1207-3/NR-1207-E
New
EEG System
BRAIN QUICK

Print article

Channels

Critical Care

view channel
Image: The permeable wearable electronics developed for long-term biosignal monitoring (Photo courtesy of CityUHK)

Super Permeable Wearable Electronics Enable Long-Term Biosignal Monitoring

Wearable electronics have become integral to enhancing health and fitness by offering continuous tracking of physiological signals over extended periods. This monitoring is crucial for understanding an... Read more

Surgical Techniques

view channel
Image: NTT and Olympus have begun the world\'s first joint demonstration experiment of a cloud endoscopy system (Photo courtesy of Olympus)

Cloud Endoscopy System Enables Real-Time Image Processing on the Cloud

Endoscopes, which are flexible tubes inserted into the body's natural openings for internal examination and biopsy collection, are becoming increasingly vital in medical diagnostics. Their minimal invasiveness... Read more

Patient Care

view channel
Image: The newly-launched solution can transform operating room scheduling and boost utilization rates (Photo courtesy of Fujitsu)

Surgical Capacity Optimization Solution Helps Hospitals Boost OR Utilization

An innovative solution has the capability to transform surgical capacity utilization by targeting the root cause of surgical block time inefficiencies. Fujitsu Limited’s (Tokyo, Japan) Surgical Capacity... Read more

Health IT

view channel
Image: First ever institution-specific model provides significant performance advantage over current population-derived models (Photo courtesy of Mount Sinai)

Machine Learning Model Improves Mortality Risk Prediction for Cardiac Surgery Patients

Machine learning algorithms have been deployed to create predictive models in various medical fields, with some demonstrating improved outcomes compared to their standard-of-care counterparts.... Read more

Point of Care

view channel
Image: The PATHFAST hs-cTnI-II high-sensitivity troponin assay has been developed for the PATHFAST Biomarker Analyzer (Photo courtesy of Polymedco)

POC Myocardial Infarction Test Delivers Results in 17 Minutes

Chest pain is the second leading cause of emergency department (ED) visits by adults in the United States, generating over 7 million visits annually. In the event of a suspected heart attack, physicians... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.